
Scandinavian ChemoTech Q1 - Positive clinical performance

Redeye leaves its comments on Scandinavian ChemoTech following the company's Q1 2023 report. The report contained no significant surprises, but the company reported slightly lower OPEX than expected. We largely maintain our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scandinavian ChemoTech Q1 - Positive clinical performance](#)